More Videos
|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- A Goldman Trading Scandal?
- The Rising Mountain of Debt May Be the Next Crisis
- Alaska Governor Sarah Palin Will Resign
- Latvian Banker Taking Souls as Collateral
- Malaysia PM Speaks to CNBC
- SEC May Reinstate Rules for Short-Selling Stocks
- Cuddle Parties Heat Up
- Your First Move For Monday July 6th
- Market 360: The Week's Best & Worst
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- BOJ Shirakawa: Japan Corporate Finance Still Tight
- China Reassures on Dollar Debate Before G8
- Obama Heads to Moscow for 'Reset' Summit
- Alcoa to Post Loss — What Does This Mean?
- A Goldman Trading Scandal?
- Top Videos: From the Black Swan to the Bond King
- Obama Plan Would Trim Back Financial Powerhouses
- Biden: 'We Misread How Bad The Economy Was'
- FedEx Sees Signs of a Turnaround: Report
RSS FEED
Text Size 
 |
AP |
Yesterday I blogged about regulatory risk and late yesterday the Food and Drug Administration provided Merck [MRK
Loading...
()
] with another example of it. The agency rejected the drugmaker's cholesterol treatment formerly known as Cordaptive and now called Tredaptive (The FDA sometimes makes companies change proposed commercial drug names for any number of reasons.)
In a press release Merck didn't divulge the FDA's problem(s) with the drug, but analysts suspect it has something to do with safety issues. Tredaptive combines Niacin with a new drug to reduce the extremely bothersome facial flushing side effects of Niacin.
Anecdotally, two co-workers at CNBC told me separately in the days leading up to the FDA decision date that they'd both taken Niacin, but had to go off of it because the turned red, tingly and hot. Abbott Labs [ABT
Loading...
()
] markets A Niacin drug under the brand name Niaspan. ABT shares are rallying on the elimination of, at least, a near-term threat to the drug which brought in $660 million in revenue last year.
Just last week European regulatory authorities recommended approval of Tredaptive. That, perhaps, goes to the point. Schering-Plough [SGP
Loading...
()
] Chairman and CEO Fred Hassan made in my interview with him last week, that he believes the regulatory, political and media environment in the U.S. is putting the country at risk of ceding its drug innovation leadership position to overseas.
Indeed, Merck has suffered two FDA slapdowns in as many days. Last Friday, the agency said no to MRK and SGP's combo allergy drug and then late Monday came the Tredaptive decision.
Analysts are all over the story. Miller-Tabak healthcare analyst writes in a stinging research note to clients: "Two non-approvals in one week. Is this a record for MRK? It seems more like PFE. We had expected this drug to be a blockbuster in the middle of the next decade. Obviously this is called into question."
And Catherine Arnold at Credit Suisse says: "MRK's late stage pipeline is seen as mediocre absent Cordaptive...."
Merck has a diet and another cholesterol drug in development, but similar drugs at competitors have not fared well. CS has banked Merck and wants to do it again.
If investors didn't realize it before, this week's events (and the week is young) are a painful lesson (unless you're on the short side of the trade) that the pharma-biotech sectors are rife with risk. Not just regulatory, but also clinical. This morning before the opening bell Genentech[DNA
Loading...
()
] and Biogen Idec [BIIB
Loading...
()
] announced their late-stage test of Rituxan on lupus didn't meet its goal. Both stocks are getting hammered.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes